VIA
JBIO

Virtus Investment Advisers’s Jade Biosciences JBIO Stock Holding History

Virtus Investment Advisers’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
21,329
+3,126
+17% +$65.2K 0.11% 217
2026
Q1 		$256K Buy
18,203
+444
+3% +$6.43K 0.07% 312
2025
Q4 		$274K Buy
+17,759
New +$208K 0.07% 283

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Investment Advisers's JBIO Position: Q2 2026 in Review

Virtus Investment Advisers increased its Jade Biosciences (JBIO) stake by 17% in Q2 2026, buying an estimated $65.2K and bringing the position to 21,329 shares worth $474K. The position accounts for 0.11% of the portfolio, ranked #217.

Virtus Investment Advisers first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Virtus Investment Advisers held 21,329 shares of Jade Biosciences worth $474K as of Q2 2026.
  • Virtus Investment Advisers bought 3,126 Jade Biosciences shares in Q2 2026, an estimated $65.2K.
  • Jade Biosciences made up 0.11% of Virtus Investment Advisers's portfolio in Q2 2026, its #217 holding.
  • Virtus Investment Advisers first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.